Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Drug: Tetracycline,Metronidazole
- Registration Number
- NCT04879992
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Brief Summary
Rifabutin has good chemical stability and low drug resistance rate in acidic gastric environment. Therefore, it is often used in combination with amoxicillin proton pump inhibitor for the rescue treatment of Helicobacter pylori. The purpose of this study was to evaluate the efficacy and safety of rifabutin-containing triple therapy versus classical bismuth-containing quadruple therapy as rescue therapy for the eradication of refractory Helicobacter pylori
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 413
- ability and willingness to participate in the study and to sign and give informed consent
- Confirmed H. pylori infection and with previous treatment experience
- Less than 18 years old
- With previous gastric surgery
- Previous history of tuberculosis
- Major systemic diseases
- Pregnancy or lactation
- Allergy to any of the study drugs Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Tetracycline Bismuth Quadruple Therapy Bismuth Potassium Citrate Esomeprazole 20mg bid, Bismuth Potassium Citrate 300mg bid, Tetracycline 500mg qid, Metronidazole 400mg qid rifabutin triple therapy amoxicillin rifabutin Esomeprazole 20mg bid, amoxicillin 1000mg bid, rifabutin 150mg bid Tetracycline Bismuth Quadruple Therapy Tetracycline,Metronidazole Esomeprazole 20mg bid, Bismuth Potassium Citrate 300mg bid, Tetracycline 500mg qid, Metronidazole 400mg qid Tetracycline Bismuth Quadruple Therapy Esomeprazole Esomeprazole 20mg bid, Bismuth Potassium Citrate 300mg bid, Tetracycline 500mg qid, Metronidazole 400mg qid rifabutin triple therapy Esomeprazole Esomeprazole 20mg bid, amoxicillin 1000mg bid, rifabutin 150mg bid
- Primary Outcome Measures
Name Time Method Helicobacter pylori eradication rate Six weeks after completion of therapy Six weeks after completion of therapy, H. pylori eradication was assessed by ¹³C-urea breath test. Eradication was
- Secondary Outcome Measures
Name Time Method Compliance rate Within 7 days after completion of therapy Compliance was defined as poor when they had taken less than 80% of the total medication
Trial Locations
- Locations (1)
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
🇨🇳Shanghai, Shanghai, China